Polaris to acquire Salfarm.

Polaris, a Nordic mid-market investment house, agreed to acquire Salfarm, a Danish player within animal pharmaceuticals. Financial terms were not disclosed. “We are very impressed by the journey that Salfarm has undergone. Today, Salfarm is a leading Danish player within animal pharmaceuticals, recognized by both suppliers and customers as a key partner and market expert in the Nordic region. Building on the strong team at Salfarm and their deep competencies and relationships, the ambition is to strengthen and and grow Salfarm’s position outside of Denmark and establish a leading player in the Nordic market,” Simon Damkjær Wille, Polaris Partner.